Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term stage-iii. Found 15 abstracts

Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. NONSURGICAL MANAGEMENT OF OROPHARYNGEAL, LARYNGEAL, AND HYPOPHARYNGEAL CANCER: THE FOX CHASE CANCER CENTER EXPERIENCE. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2011 Oct;33(10):1433-40.   PMCID: Not NIH Funded
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology. 2011 Mar;22(3):515-23.   PMCID: PMC3105293
Lango MN, Egleston B, Ende K, Feigenberg S, D'Ambrosio DJ, Cohen RB, Ahmad S, Nicolaou N, Ridge JA. IMPACT OF NECK DISSECTION ON LONG-TERM FEEDING TUBE DEPENDENCE IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH PRIMARY RADIATION OR CHEMORADIATION. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2010 Mar;32(3):341-7.   PMCID: NIHMS198194
Rose PG, Tian CQ, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2010 May;117(2):324-9.   PMCID: NIH funded - needs PMCID
Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer. 2005 Nov 03;15:212-20.
McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in ovarian cancer. Annals of Oncology. 1999 Jan;10:29-34.
Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Seminars in Oncology. 1999 Feb;26(1):84-9.
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. Journal of Clinical Oncology. 1999 Jul;17(7):2198-207.
Socinski MA, Langer CJ. Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. Seminars in Oncology. 1999 Oct;26(5):51-61.
Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Seminars in Oncology. 1998 Jun;25(3):326-34.
Corn BW, Hanlon AL, Pajak TF, Owen J, Hanks GE. Technically Accurate Intracavitary Insertions Improve Pelvic Control and Survival among Patients with Locally Advanced- Carcinoma of the Uterine Cervix. Gynecologic Oncology. 1994 Jun;53(3):294-300.
Ozols RF. Treatment of Ovarian-Cancer - Current Status. Seminars in Oncology. 1994 Apr;21(2):1-9.
Curran WJ, Herbert SH, Stafford PM, Sandler HM, Rosenthal SA, McKenna WG, Hughes E, Dougherty MJ, Keller S. Should Patients with Postresection Locoregional Recurrence of Lung-Cancer Receive Aggressive Therapy. International Journal of Radiation Oncology Biology Physics. 1992 Jan;24(1):25-30.
Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J. Hexamethylmelamine and Low or Moderate Dose Cisplatin with or without Pyridoxine for Treatment of Advanced Ovarian-Carcinoma - a Study of the Eastern Cooperative Oncology Group. Cancer Investigation. 1992 Jan;10(1):1-9.
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis RL, Odwyer PJ. Phase-Ii Trial of Thio-Tepa in Relapsed and Refractory Ovarian- Carcinoma. Gynecologic Oncology. 1991 Dec;43(3):242-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term stage-iii

stage-iii carcinoma randomized trial survival doxorubicin cancer cisplatin cyclophosphamide chemotherapy combination chemotherapy gynecologic-oncology-group paclitaxel radiotherapy oncology-group radiation surgery disease 1st-line treatment trial system quality-of-life platinum-refractory ovarian cytoreductive 2nd-line therapy Response laparotomy organ preservation dose Gynecologic Oncology Group (GOG) protocols surgical-treatment cell lung-cancer inflammatory breast cancer phase-i trial recurrent hematopoietic rescue growth-factor new drugs phase-ii-trial Disease control cell-lung-cancer squamous-cell carcinoma improved survival guidelines look laparotomy vinorelbine neck-cancer bone-marrow transplantation high-dose carboplatin phase-iii peritoneal carcinoma lung neoplasm platinum-resistant colony-stimulating factor phase-ii breast-cancer adjuvant therapy tables 3-hour infusion squamous-cell carcinomas benefit dysphagia epithelial ovarian computed-tomography Survival randomized-trial united-states stem-cell transplantation treatment outcomes neoadjuvant chemotherapy care reduce taxanes pegylated liposomal ifosfamide cis-platinum Progression-free 2nd- follow-up previously untreated patients intraperitoneal cisplatin phase-iii trial taxol ovarian cancer intraperitoneal therapy rhoc-gtpase bronchogenic-carcinoma ovarian-cancer topotecan cisplatin plus cyclophosphamide carboplatin adenocarcinoma standard therapy platinum drug stricture tumor failure patterns human-papillomavirus 2nd-look primary peritoneal cancer concurrent chemoradiation intensive therapy head and neck cancer toxicity cyclophosphamide plus cisplatin Ovarian carcinoma leucovorin Platinum-resistant phase-i swallowing function management radiation-therapy head positron-emission-tomography phase-ii trial predict local-control predictors debulking surgery
Last updated on Monday, July 06, 2020